Qualitative thrombelastographic detection of tissue factor in human plasma

Vance G Nielsen, Paul Audu, Lana Cankovic, Ralph T. Lyerly, Brad L. Steenwyk, Valerie Armstead, Garry Powell

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

BACKGROUND: Tissue factor (TF) is the principal in vivo initiator of coagulation, with normal circulating TF concentrations reported to be approximately 23-158 pg/mL. However, patients with atherosclerosis or cancer have been reported to have TF concentrations ranging between 800 and 9000 pg/mL. Of interest, thrombelastographic (TEG®)-based measures of clot initiation and propagation have demonstrated hypercoagulability in such patients at risk for thromboembolic events. Thus, our goal in the present investigation was to establish a concentration-response relationship of the effect of TF on TEG® variables, and determine specificity of TF-mediated events with a monoclonal TF antibody. METHODS: Thrombelastography was performed on normal human plasma exposed to 0, 500, 1000, or 2000 pg/mL TF. Additional experiments with plasma exposed to 0 or 750 pg/mL TF in the presence or absence of a monoclonal TF antibody (1:360 dilution, 10 min incubation) were also performed. Clot initiation time (R) and the speed of clot propagation (MRTG, maximum rate of thrombus generation) were determined. RESULTS: The addition of TF to normal plasma resulted in a significant, concentration-dependent decrease in R and increase MRTG values. The addition of TF antibody to samples with TF significantly increased R and decreased MRTG values compared to samples with TF addition. CONCLUSIONS: In conclusion, changes in TEG® variables in conjunction with use of a TF antibody can detect pathological concentrations of TF in human plasma in vitro. Further investigation is warranted to determine if TEG®-based monitoring could assist in the detection and prevention of TF-initiated thromboembolic events.

Original languageEnglish (US)
Pages (from-to)59-64
Number of pages6
JournalAnesthesia and Analgesia
Volume104
Issue number1
DOIs
StatePublished - Jan 2007
Externally publishedYes

Fingerprint

Thromboplastin
Thrombosis
Antibodies
Thrombelastography
Thrombophilia

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Nielsen, V. G., Audu, P., Cankovic, L., Lyerly, R. T., Steenwyk, B. L., Armstead, V., & Powell, G. (2007). Qualitative thrombelastographic detection of tissue factor in human plasma. Anesthesia and Analgesia, 104(1), 59-64. https://doi.org/10.1213/01.ane.0000248223.05152.a1

Qualitative thrombelastographic detection of tissue factor in human plasma. / Nielsen, Vance G; Audu, Paul; Cankovic, Lana; Lyerly, Ralph T.; Steenwyk, Brad L.; Armstead, Valerie; Powell, Garry.

In: Anesthesia and Analgesia, Vol. 104, No. 1, 01.2007, p. 59-64.

Research output: Contribution to journalArticle

Nielsen, VG, Audu, P, Cankovic, L, Lyerly, RT, Steenwyk, BL, Armstead, V & Powell, G 2007, 'Qualitative thrombelastographic detection of tissue factor in human plasma', Anesthesia and Analgesia, vol. 104, no. 1, pp. 59-64. https://doi.org/10.1213/01.ane.0000248223.05152.a1
Nielsen, Vance G ; Audu, Paul ; Cankovic, Lana ; Lyerly, Ralph T. ; Steenwyk, Brad L. ; Armstead, Valerie ; Powell, Garry. / Qualitative thrombelastographic detection of tissue factor in human plasma. In: Anesthesia and Analgesia. 2007 ; Vol. 104, No. 1. pp. 59-64.
@article{3ed3d126b5404b16a5f1c760e95ee4af,
title = "Qualitative thrombelastographic detection of tissue factor in human plasma",
abstract = "BACKGROUND: Tissue factor (TF) is the principal in vivo initiator of coagulation, with normal circulating TF concentrations reported to be approximately 23-158 pg/mL. However, patients with atherosclerosis or cancer have been reported to have TF concentrations ranging between 800 and 9000 pg/mL. Of interest, thrombelastographic (TEG{\circledR})-based measures of clot initiation and propagation have demonstrated hypercoagulability in such patients at risk for thromboembolic events. Thus, our goal in the present investigation was to establish a concentration-response relationship of the effect of TF on TEG{\circledR} variables, and determine specificity of TF-mediated events with a monoclonal TF antibody. METHODS: Thrombelastography was performed on normal human plasma exposed to 0, 500, 1000, or 2000 pg/mL TF. Additional experiments with plasma exposed to 0 or 750 pg/mL TF in the presence or absence of a monoclonal TF antibody (1:360 dilution, 10 min incubation) were also performed. Clot initiation time (R) and the speed of clot propagation (MRTG, maximum rate of thrombus generation) were determined. RESULTS: The addition of TF to normal plasma resulted in a significant, concentration-dependent decrease in R and increase MRTG values. The addition of TF antibody to samples with TF significantly increased R and decreased MRTG values compared to samples with TF addition. CONCLUSIONS: In conclusion, changes in TEG{\circledR} variables in conjunction with use of a TF antibody can detect pathological concentrations of TF in human plasma in vitro. Further investigation is warranted to determine if TEG{\circledR}-based monitoring could assist in the detection and prevention of TF-initiated thromboembolic events.",
author = "Nielsen, {Vance G} and Paul Audu and Lana Cankovic and Lyerly, {Ralph T.} and Steenwyk, {Brad L.} and Valerie Armstead and Garry Powell",
year = "2007",
month = "1",
doi = "10.1213/01.ane.0000248223.05152.a1",
language = "English (US)",
volume = "104",
pages = "59--64",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Qualitative thrombelastographic detection of tissue factor in human plasma

AU - Nielsen, Vance G

AU - Audu, Paul

AU - Cankovic, Lana

AU - Lyerly, Ralph T.

AU - Steenwyk, Brad L.

AU - Armstead, Valerie

AU - Powell, Garry

PY - 2007/1

Y1 - 2007/1

N2 - BACKGROUND: Tissue factor (TF) is the principal in vivo initiator of coagulation, with normal circulating TF concentrations reported to be approximately 23-158 pg/mL. However, patients with atherosclerosis or cancer have been reported to have TF concentrations ranging between 800 and 9000 pg/mL. Of interest, thrombelastographic (TEG®)-based measures of clot initiation and propagation have demonstrated hypercoagulability in such patients at risk for thromboembolic events. Thus, our goal in the present investigation was to establish a concentration-response relationship of the effect of TF on TEG® variables, and determine specificity of TF-mediated events with a monoclonal TF antibody. METHODS: Thrombelastography was performed on normal human plasma exposed to 0, 500, 1000, or 2000 pg/mL TF. Additional experiments with plasma exposed to 0 or 750 pg/mL TF in the presence or absence of a monoclonal TF antibody (1:360 dilution, 10 min incubation) were also performed. Clot initiation time (R) and the speed of clot propagation (MRTG, maximum rate of thrombus generation) were determined. RESULTS: The addition of TF to normal plasma resulted in a significant, concentration-dependent decrease in R and increase MRTG values. The addition of TF antibody to samples with TF significantly increased R and decreased MRTG values compared to samples with TF addition. CONCLUSIONS: In conclusion, changes in TEG® variables in conjunction with use of a TF antibody can detect pathological concentrations of TF in human plasma in vitro. Further investigation is warranted to determine if TEG®-based monitoring could assist in the detection and prevention of TF-initiated thromboembolic events.

AB - BACKGROUND: Tissue factor (TF) is the principal in vivo initiator of coagulation, with normal circulating TF concentrations reported to be approximately 23-158 pg/mL. However, patients with atherosclerosis or cancer have been reported to have TF concentrations ranging between 800 and 9000 pg/mL. Of interest, thrombelastographic (TEG®)-based measures of clot initiation and propagation have demonstrated hypercoagulability in such patients at risk for thromboembolic events. Thus, our goal in the present investigation was to establish a concentration-response relationship of the effect of TF on TEG® variables, and determine specificity of TF-mediated events with a monoclonal TF antibody. METHODS: Thrombelastography was performed on normal human plasma exposed to 0, 500, 1000, or 2000 pg/mL TF. Additional experiments with plasma exposed to 0 or 750 pg/mL TF in the presence or absence of a monoclonal TF antibody (1:360 dilution, 10 min incubation) were also performed. Clot initiation time (R) and the speed of clot propagation (MRTG, maximum rate of thrombus generation) were determined. RESULTS: The addition of TF to normal plasma resulted in a significant, concentration-dependent decrease in R and increase MRTG values. The addition of TF antibody to samples with TF significantly increased R and decreased MRTG values compared to samples with TF addition. CONCLUSIONS: In conclusion, changes in TEG® variables in conjunction with use of a TF antibody can detect pathological concentrations of TF in human plasma in vitro. Further investigation is warranted to determine if TEG®-based monitoring could assist in the detection and prevention of TF-initiated thromboembolic events.

UR - http://www.scopus.com/inward/record.url?scp=33847608690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847608690&partnerID=8YFLogxK

U2 - 10.1213/01.ane.0000248223.05152.a1

DO - 10.1213/01.ane.0000248223.05152.a1

M3 - Article

C2 - 17179243

AN - SCOPUS:33847608690

VL - 104

SP - 59

EP - 64

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 1

ER -